Javiera Constanza Obreque Castro
Investigadora Postdoctoral
CECAN - PUC
Santiago, Chile
Inmuno oncología y modelos tridimensionales en cáncer Biomarcadores inmune en cáncer
-
Bioquímica, UNIVERSIDAD DE SANTIAGO DE CHILE. Chile, 2013
-
Doctora en Ciencias Médicas, PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE. Chile, 2024
-
Estudios Clínicos, UNIVERSIDAD DE CHILE. Chile, 2015
-
Profesor auxiliar Part Time
PONTIFICIA UNIVERSIDAD CATOLICA DE CHILE
Médicina
Santiago, Chile
2020 - 2023
-
Ayudante Other
UNIVERSIDAD DE SANTIAGO DE CHILE
Química y Biología
Santiago, Chile
2011 - 2012
-
Ayudante de Laboratorio Other
UNIVERSIDAD SANTO TOMAS
Santiago, Chile
2011 - 2013
-
Investigadora Postdoctoral Full Time
Pontificia Universidad Católica de Chile
Chile
2024 - 2024
-
Asistente de Investigación Full Time
Pontificia Universidad Católica de Chile
Santiago, Chile
2013 - 2018
-
Tesista Doctoral Full Time
Pontificia Universidad Católica de Chile
Santiago, Chile
2020 - 2024
-
Clinical Research Assistant Part Time
Levita Magnetics
Santiago, Chile
2022 - 2023
Cursos de Pre y Post Grado
Annual Meeting Chilean society for Cell Biology, 2023
Evaluation of T cells response in Galbladder cancer patient-derived organoids co-cultured with immune cells. Obreque J, Ávalos-Guajardo YY, Castillo A, García P, Roa JC, & Bizama C. XXXV Annual Meeting Chilean Society for Cell Biology, November 6-10, 2023, Puerto Varas, Chile.
Congress of Medical Oncology, 2019
Establishment and characterization of gallbladder cancer-derived organoids as a new ex vivo model for precision medicine. Javiera Obreque, Felipe Suárez, Luis Vergara, Ángel Castillo, Patricia García, Daniela Nahuelquén, Juan Carlos Roa, Bruno Nervi, Eduardo Viñuela, Gloria Aguayo, Sabrina Muñiz y Carolina Bizama.
IV Chilean Congress of Medical Oncology, Santa Cruz, Chile Agosto de 2019
-
Beca Dosctorado Nacional
ANID
Chile, 2018
Beca ANID
Adjuvant capacity of the aromatic geranyl derivative Filifolinone in salmonids |
Genomically Stable Gastric Cancer: YAP1 as a predictor ofstandard therapy response and novel target for precisionmedicine |
PLATFORM OF THERAPY RESPONSE PREDICTION AND DRUG SCREENING USING GALLBLADDER CANCER PATIENTS-DERIVED ORGANOIDS |
HO-1 EXPRESSION PROTECTS FROM KIDNEY DAMAGE INDUCED BY INNATE IMMUNITY DURING LUPUS NEPHRITIS |
HO-1 EXPRESSION PROTECTS FROM KIDNEY DAMAGE INDUCED BY INNATE IMMUNITY DURING LUPUS NEPHRITIS |
Desarrollo de Inmunoterapia celular para el tratamiento del Lupus Eritematoso Sistémico basada en Células Dendríticas Autólogas |
INMUNOTERAPIA BASADA EN CÉLULAS DENDRÍTICAS TOLEROGÉNICAS AUTÓLOGAS PARA LUPUS ERITEMATOSO SISTÉMICO (LES) |
Autoimnunidad |
OBTAINING NATURAL PRODUCTS WITH IMMUNOSTIMULATORY AND/OR ADJUVANT ACTIVITY IN SALMONID CELLS FOR VETERINARY APPLICATIONS=> OPTIMIZATION OF COMMERCIAL VACCINES |
ROLE OF DENDRITIC CELLS AT DRIVING THE T CELL RESPONSE LEADING TO SYSTEMIC LUPUS ERYTHEMATOSUS=> IMPLICATIONS AS A NOVEL MECHANISM FOR THERAPEUTIC TARGETING. |
Advances towards the use of gastrointestinal tumor patient-derived organoids as a therapeutic decision-making tool |